Improvement in clinical outcomes of patients with heart failure and active cocaine use after β-blocker therapy.

β-Blocker use in cocaine users with heart failure with a reduced ejection fraction is associated with a lower NYHA functional class and a higher LVEF at 12-month follow-up. No major adverse cardiovascular events were observed.